Dupilumab is a medication that works by targeting specific parts of the immune system. It helps reduce inflammation in the body. In this trial, it is being tested as a treatment for bullous pemphigoid, which is an autoimmune skin condition that causes large, fluid-filled blisters. The medication is administered through injection under the skin.

Oral Corticosteroids (OCS) are anti-inflammatory medications that help suppress the immune system response. They are commonly used to treat various inflammatory and autoimmune conditions, including bullous pemphigoid. The trial aims to see if patients can achieve remission from their condition without needing these steroids when using dupilumab.

Bullous Pemphigoid – A rare autoimmune skin disorder characterized by the formation of large, fluid-filled blisters (bullae) that develop on the surface of the skin. The condition typically begins with redness and itching of the skin, followed by the appearance of blisters that most commonly occur on the arms, legs, abdomen, and flexor surfaces. The blisters form because the immune system mistakenly attacks proteins that help hold the layers of skin together. The condition primarily affects older adults and tends to develop gradually over weeks or months. The blisters are typically firm, and the skin around them may appear either normal or reddened.